Kingsbury on NSF, Biotech Regulation

David T Kingsbury, assistant director for biological, behavioral and social sciences at the National Science Foundation, has been described as the Reagan administration's point man on biotechnology. As chairman of the Biotechnology Science Coordinating Committee formed under the White House Office of Science and Technology Policy, Kingsbury was the principal architect of the Coordinated Framework for Biotechnology, which President Reagan signed last June. After receiving his Ph.D. in 1971, Kings

| 10 min read

Register for free to listen to this article
Listen with Speechify
0:00
10:00
Share

After receiving his Ph.D. in 1971, Kingsbury taught microbiology at the University of California at Irvine. In 1981 he became a professor of medical microbiology and virology at the University of California at Berkeley, from which he is now on leave. His research interests include pathogenesis of the slow viruses, infection by microbial pathogens and molecular diagnostic techniques in medical microbiology.

Kingsbury, who joined the NSF in 1984, is also an adjunct professor at George Washington University. He was interviewed in his NSF office in Washington last month by Tabitha M. Powledge, editor of The Scientist. This is an edited version of their talk.

Over the next five years, the balance will change a little bit. Several things are going to happen. One is that NSF is going to be playing a much more significant role in education and human resource development. We're going to change from our recent focus ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies